Brainsway Ltd
brainsway.comWhat Do They Do?
Sells Deep TMS systems for depression, obsessive-compulsive disorder and smoking cessation to psychiatrists and other treatment facilities.
20-F for FY2025, filed Apr 20, 2026BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly…View ↗
We have also received CE Mark for a variety of psychiatric and neurological indications. We are focused on increasing global awareness of…View ↗
Our first commercial H1 Coil Deep TMS product received clearance from the FDA in 2013 for the treatment of MDD in adult patients who have…View ↗
Who Are Their Customers?
In the United States, psychiatrists’ offices and other facilities buy or lease Deep TMS systems through BrainsWay’s own sales channel.
20-F for FY2025, filed Apr 20, 2026Our first commercial H1 Coil Deep TMS product received clearance from the FDA in 2013 for the treatment of MDD in adult patients who have…View ↗
The United States is our primary and most strategic market, representing approximately 85%, 81% and 75% of our revenues for the years ended…View ↗
In the United States, we sell or lease Deep TMS systems by one of the following two methods: (i) a fixed-fee lease model in which the Deep…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 15 cents of every revenue dollar as net income in .
20-F for FY2025, filed Apr 20, 2026
How Are They Changing?
Broader MDD patient group
The MDD offering has expanded from adult patients to include adolescents, for whom the treatment is used as an adjunct therapy.
20-F for FY2022, filed Mar 27, 2023 20-F for FY2025, filed Apr 20, 2026Our first commercial H1 Coil Deep TMS product received clearance from the FDA in 2013 for the treatment of MDD in adult patients who have…View ↗
In November 2025, the FDA cleared an expansion of our existing MDD clearance allowing for the treatment of adolescent patients (ages 15-21)…View ↗
Loading...
